Gagandeep Brar, MD
Hematology & Oncology · Mission Hills, CANPI 1528323177
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,282 of the $6,758 with a category attached, or 63.4%. 15 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 41.1% of the total.
Across 25 payments — averaging $270.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$3K
- Exelixis Inc.$2K
- Genentech USA, Inc.$2K
- Sanofi$203
- Astellas Pharma US Inc$192
- Ipsen Biopharmaceuticals, Inc$68
- plus $318 from 9 others
Across 15 payments — averaging $19,455 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$213K
- AstraZeneca$51K
- AbbVie$22K
- Jazz Pharmaceuticals Inc.$6K
What the payments were for
- Consulting fees$1,51522%
- Speaking & faculty fees$4,28263%
- Food & beverage$76911%
- Education$1923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 2 | $2,776 |
| Exelixis Inc. | 2 | $1,687 |
| Genentech USA, Inc. | 1 | $1,515 |
| Sanofi | 2 | $203 |
| Astellas Pharma US Inc | 2 | $192 |
| Ipsen Biopharmaceuticals, Inc | 3 | $68 |
| Array Biopharma Inc | 3 | $66 |
| Tempus AI, Inc | 2 | $56 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Foundation Medicine, Inc. | 1 | $25 |
| Incyte Corporation | 1 | $25 |
| AstraZeneca | 1 | $21 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,758 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LonsurfTrifluridine/Tipiracil Hcl | 20 | $156,004 |
| EliquisApixaban | 22 | $13,007 |
| Dexamethasone | 53 | $978 |
| Ondansetron Hcl | 79 | $905 |
| Gabapentin | 36 | $501 |
| Doxycycline Hyclate | 12 | $384 |
| Oxycodone Hcl | 15 | $358 |
| Pantoprazole Sodium | 15 | $306 |
| Ondansetron OdtOndansetron | 13 | $297 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 25 | $284 |
| Prochlorperazine Maleate | 17 | $280 |
| Duloxetine Hcl | 11 | $90 |
| Triamcinolone Acetonide | 14 | $45 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Mission Hills
- Sarmen SarkissianMission Hills$675K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.